ABCA1 and atherosclerosis: Current research data indicate that Danlou tablet inhibits atherosclerosis via various mechanisms, including the inhibition of Angptl4 protein level through the HIF-1α-Angptl4 mRNA signaling pathway (Tang et al., 2020), inhibition of the NF-κB-mediated inflammatory response (Gao et al., 2020), and prevention of PPARα/ABCA1-regulated lipid deposition (Hao et al., 2019).